{name}
{subtitle}
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~16 mi. (Swansea, United Kingdom, +247 more cities)
facility
Local Institution
biomarker
ER Positive, +1 more biomarker
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
city
~16 mi. (Swansea, United Kingdom, +174 more cities)
facility
Local Institution
drug
chemoradiotherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~44 mi. (Cardiff, United Kingdom, +201 more cities)
facility
Cardiff & Vale University Health Board /ID# 221236
drug
azacitidine, +1 more drug
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
~44 mi. (Cardiff, United Kingdom, +197 more cities)
facility
Cardiff & Vale University Health Board /ID# 215906
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
drug
azacitidine, +1 more drug
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
city
~44 mi. (Cardiff, United Kingdom, +45 more cities)
facility
University Hospital of Wales
condition
Multiple Myeloma, +2 more conditions
drug
CC-92480, +1 more drug
drug type
hormone therapy, +1 more type
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
city
~44 mi. (Cardiff, United Kingdom, +8 more cities)
facility
Velindre Cancer Center at Velinde Hospital
biomarker
ER Negative, +2 more biomarkers
drug
ceralasertib, +2 more drugs
drug type
immunotherapy, +1 more type